Epilepsy Research
Volume 28, Issue 1 , Pages 63-72 , July 1997

Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin

Received 9 May 1996 ,Revised 11 April 1997 ,Accepted 25 April 1997.

References 

  1. Reynolds EH, Elwes RDC, Shorvon SD. Why does epilepsy become intractable? Prevention of chronic epilepsy. Lancet. 1983;2:952–954
  2. Patsalos P, Sander J. New antiepileptic drugs-a review of their current status and clinical potential. Cns Drugs. 1994;2:40–77
  3. Bauer JS, Lenders T, Bettig U, Elger C. Efficacy and tolerability of tiagabine-results of an add-on study in patients with refractory partial seizures. J Epilepsy. 1995;8:83–86
  4. Richens A, Chadwick DW, Duncan JS, Dam M, Gram L, Mikkelsen M, et al. Adjunctive treatment of partial seizures with tiagabine: A placebo controlled trial. Epilepsy Res. 1995;21:37–42
  5. Fink-Jensen A, Suzdak PD, Swedberg MDB, Judge ME, Hansen L, Nielsen PG. The γ-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur J Pharmacol. 1992;220:197–201
  6. Borden L, Dhar T, Smith K, Weinshank R, Branchek T, Gluchowski C. Tiagabine, SK-&-F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol. 1994;269:219–224
  7. Braestrup C, Nielsen EB, Sonnewald U, Knutsen LJS, Andersen KE, Jansen JA, et al. (R)-N-(4,4-bis(3-methyl-2thienyl)but-3-en-1-yl)nipecotic acid (tiagabine) binds with high affinity to the brain GABA uptake carrier. J Neurochem. 1990;54:639–647
  8. Nielsen EB, Suzdak PD, Andersen KE, Knutsen LJS, Sonnewald U, Braestrup C. Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol. 1991;196:257–266
  9. Smith S, Parvez N, Chapman A, Meldrum B. The γ-aminobutyric-acid uptake inhibitor, tiagabine, is anticonvulsant in 2 animal-models of reflex epilepsy. Eur J Pharmacol. 1995;273:259–265
  10. Cheung H, Kamp D, Harris E. An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium-channels. Epilepsy Res. 1992;13:107–112
  11. Grove J, Schecter PJ, Tell G, Koch-Weser J, Sjoerdsma A, Warter JM, et al. Increased γ-aminobutyric acid (GABA), homocarnisine and β-alanine in the cerebrospinal fluid of patients treated with γ-vinyl GABA (4-amino-hex-5-enoic acid). Life Sci. 1981;28:2431–2437
  12. Jung MJ, Lippert B, Metcalf B, Bohlen P, Schecter PJ. γ-vinyl GABA (4-amino-hex-5-enoic acid) a new irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J Neurochem. 1977;29:797–802
  13. Honmou OK, Kosics J, Richerson G. Gabapentin potentiates the conductance increase induced by nipecotic acid in CA1 pyramidal neurons in-vitro. Epilepsy Res. 1995;20:193–202
  14. Honmou OK, Oyeleese A, Kocsis J. The anticonvulsant gabapentin enhances promoted release of GABA in hippocampus-a field potential analysis. Brain Res. 1995;692:273–277
  15. Petroff OR, Behar K, Lamoureux D, Mattson R. Gabapentin increases brain γ-aminobutyric-acid levels in patients with epilepsy. Ann Neurol. 1995;38:295–296
  16. Löscher W, Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. 1988;2:145–181
  17. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. New York: Academic press, 1986.
  18. Racine RJ. Modification of seizure activity by electrical stimulation: II. Motor seizure. Electroencephal Clin Neurophysiol. 1972;32:281–294
  19. Litchfield JT, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 1949;96:99–113
  20. Leiderman D. Gabapentin as add-on therapy for refractory partial epilepsy-results of 5 placebo-controlled trials. Epilepsia. 1994;35:S74–S76
  21. Reynolds E. Gamma-vinyl GABA (vigabatrin)-clinical-experience in adult and adolescent patients with intractable epilepsy. Epilepsia. 1992;33:S30–S35
  22. Smith DB, Baker G, Davies G, Dewey M, Chadwick D. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia. 1993;34:312–322
  23. Bartoszyk GD, Meyerson N, Reimann W, Satzinger G, Von Hodenberg A. Gabapentin. In: Meldrum BS, Porter RJ, editors. New Anticonvulsant Drugs. London: Libbey, 1986:147–163.
  24. Smith S, Alzubaidy Z, Chapman A, Meldrum B. Excitatory amino-acid antagonists, lamotrigine and BW-1003C87 as anticonvulsants in the genetically epilepsy-prone rat. Epilepsy Res. 1993;15:101–111
  25. Vergnes M, Marescaux C, Pathophysiological mechanisms underlying genetic absence epilepsy in rats. In: Malafosse A, Genton P, Hirsch E, Marescaux C, Broglin D, Bernasconi R, editors. Idiopathic generalized epilepsies: clinical, experimental and genetic aspects. London: John Libbey and Company Ltd, 1994:151–168.
  26. Lamb RJ, Miller AA. Effect of lamotrigine and some known anticonvulsant drugs on visually-evoked after-discharge in the conscious rat. Br J Pharm. 1985;86:765–772
  27. Buchanan N. Lamotrigine in the treatment of absence seizures. Acta Neurol Scand. 1995;92:348
  28. Löscher W, Jackel R, Muller F. Anticonvulsant and proconvulsant effects of inhibitors of GABA degradation in the amygdala-kindling model. Eur J Pharmacol. 1989;163:1–14
  29. Foot M, Wallace J. Gabapentin. In: Pisani F, Perucca E, Avanzani G, Richens A, editors. New Antiepileptic Drugs. Elsevier Science Publishers, 1991:109–114.
  30. Otsuki K, Satò K, Yarnada N, Kuroda S, Morimoto K. Anticonvulsant effects of lamotrigine, a novel antiepileptic drug on amygdaloid and hippocarnpal kindled seizures in rats. Jpn J Neuropsychopharmacol. 1995;17:35–42
  31. Schwark WS, Löscher W. Comparison of the anticonvulsant effects of two novel GABA uptake inhibitors and diazepam in amygdaloid kindled rats. Naunyn-Scmeideberg's Arch Pharmacol. 1985;329:367–371
  32. Albertson TE, Peterson SL, Stark LG. Anticonvulsant drugs and their antagonism of kindled amygdaloid seizures in rats. Neuropharmacology. 1980;19:643–652
  33. Ikegaki N, Saito N, Hashima M, Tanaka C. Production of specific antibodies against GABA-transporter subtypes (GAT1, GAT2, GAT3) and their application to immunocytochemistry. Brain Res. 1994;26:47–54
  34. Hill DR, Surnan-Chanhan N, Woodruf GN. Localisation of 3H-gabapentin to a novel site in rat brain: autoradiographic studies. Eur J Pharmacol. 1993;244:303–309
  35. Löscher WR, Rundfeldt C, Honack D. Pharmacological characterization of phenytoin-resistant amygdala-kindled rats, a new model of drug-resistant partial epilepsy. Epilepsy Res. 1993;15:207–219

PII: S0920-1211(97)00031-4

Epilepsy Research
Volume 28, Issue 1 , Pages 63-72 , July 1997

Article Tools

* Image Usage & Resolution